ARYx Therapeutics (OTC: ARYX)

ARYx Therapeutics Return vs. S&P

ARYx Therapeutics Company Info

ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. Its products include Naronapride, a proprietary serotonin type 4 (5HT4) for the treatment of multiple gastrointestinal disorders, Budiodarone, a proprietary compound in Phase 2 development for the treatment of atrial fibrillation, Tecarfarin, a novel compound for oral anti-coagulation therapy, and ATI-9242, a typical antipsychotic for the treatment of schizophrenia and other psychiatric disorders. The company was founded on February 28, 1997 by Peter G. Milner and Pascal Druzgala and is headquartered in Fremont, CA.

Valuation